Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AKRO Akero Therapeutics

停牌 12-11 13:02:59 EST

54.65

+0.00

0.00%

最高54.65	最低54.65	成交量0.00
今开54.65	昨收54.65	日振幅0.00%
总市值44.99亿	流通市值37.04亿	总股本8,232万
成交额0.00	换手率0.00%	流通股本6,777万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AKRO","market":"US","secType":"STK","nameCN":"Akero Therapeutics","latestPrice":54.65,"timestamp":1765476179555,"preClose":54.65,"halted":3,"volume":0,"delay":0,"floatShares":67772434,"shares":82324445,"eps":-3.741847,"marketStatus":"停牌","change":0,"latestTime":"12-11 13:02:59 EST","open":54.65,"high":54.65,"low":54.65,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.741847,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"listingDate":1561003200000,"exchange":"NASDAQ","adjPreClose":54.65,"volumeRatio":0},"requestUrl":"/m/hq/s/AKRO/wiki","defaultTab":"wiki","newsList":[{"id":"2590344084","title":"诺和诺德完成对生物制药公司Akero的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344084","media":"动脉网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344084?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:00","pubTimestamp":1765288800,"startTime":"0","endTime":"0","summary":"诺和诺德12月9日宣布已成功完成对生物制药公司Akero Therapeutics的收购。此次收购以每股54美元现金（总价值达47亿美元）及一项不可转让的或有价值权（CVR）作为交易对价，全面收购了Akero所有已发行的普通股及等价物。随着交易的圆满结束，Akero正式成为诺和诺德旗下的全资子公司，其普通股也将随之从纳斯达克全球精选市场退市，不再进行上市交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512092209119798b1ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512092209119798b1ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4007","AKRO","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","IE00BKVL7J92.USD","BK4585","BK4599","BK4588","LU1093756325.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2590341068","title":"诺和诺德：已完成对Akero的收购，其普通股将不再在纳斯达克全球精选市场上市或交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341068","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590341068?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:56","pubTimestamp":1765288564,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4599","LU1093756168.USD","NVO","BK4588","BK4007","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","IE00BKVL7J92.USD","BK4532","AKRO","BK4585"],"gpt_icon":0},{"id":"1116707952","title":"Akero Therapeutics在2025年第76届AASLD肝脏会议上展示Efruxifermin的Phase 2B Symmetry和Harmony试验新分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1116707952","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116707952?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:01","pubTimestamp":1762516891,"startTime":"0","endTime":"0","summary":"Akero Therapeutics在2025年第76届AASLD肝脏会议上展示Efruxifermin的Phase 2B Symmetry和Harmony试验新分析","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4505","AKRO","BK4139"],"gpt_icon":0},{"id":"1131577985","title":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1131577985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131577985?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:02","pubTimestamp":1761044561,"startTime":"0","endTime":"0","summary":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会，以继续推动公司的发展进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4585","BK4532","BK4139","BK4588","BK4505","LEGN","AKRO"],"gpt_icon":0},{"id":"1110937266","title":"Akero Therapeutics：若交易在特定情况下终止，公司将向Novo Nordisk支付1.65亿美元终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1110937266","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110937266?lang=zh_cn&edition=full","pubTime":"2025-10-10 04:48","pubTimestamp":1760042937,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件显示，Akero Therapeutics表示，如果相关交易在某些特定情况下被终止，该公司将需要向Novo Nordisk支付1.65亿美元的终止费用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7634fea479edb90013bb48394ae3ce34","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AKRO","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2574163965","title":"美股异动｜生物技术公司Akero Therapeutics涨约16.5%，获诺和诺德溢价约16%收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2574163965","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574163965?lang=zh_cn&edition=full","pubTime":"2025-10-09 21:51","pubTimestamp":1760017871,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7634fea479edb90013bb48394ae3ce34","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4505","AKRO","LENZ","LU1093756168.USD","LU1093756325.SGD","BK4539","IE00BKVL7J92.USD","BK4007","BK4588","BK4599","NVO","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4585","BK4139"],"gpt_icon":0},{"id":"1173676135","title":"Novo Nordisk拟最高52亿美元收购 Akero Therapeutics盘前大涨16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173676135","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173676135?lang=zh_cn&edition=full","pubTime":"2025-10-09 18:07","pubTimestamp":1760004436,"startTime":"0","endTime":"0","summary":"受Novo Nordisk计划以最高52亿美元价格收购消息推动，Akero Therapeutics股价在盘前交易中上涨16.7%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7634fea479edb90013bb48394ae3ce34","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","AKRO","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"1130478889","title":"诺和诺德将以每股54美元现金收购Akero Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1130478889","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130478889?lang=zh_cn&edition=full","pubTime":"2025-10-09 18:06","pubTimestamp":1760004404,"startTime":"0","endTime":"0","summary":"10月9日，$Akero Therapeutics(AKRO)$美股盘前涨超16%！报道称$诺和诺德(NVO)$将以每股54美元现金收购Akero $Therapeutics(LENZ)$。诺和诺德盘前一度跌近2%。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7634fea479edb90013bb48394ae3ce34","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德将以每股54美元现金收购Akero Therapeutics","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4532","BK4007","LU0154236417.USD","AKRO","LENZ","BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","BK4505","NVO","BK4588","BK4139","LU1093756168.USD","BK4539","BK4599"],"gpt_icon":0},{"id":"2518447760","title":"Akero Therapeutics, Inc.2024财年实现净利润-2.52亿美元，同比减少65.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518447760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518447760?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449652,"startTime":"0","endTime":"0","summary":"3月9日，Akero Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.52亿美元，同比减少65.79%；其中营业收入为0.00美元，每股基本收益为-3.75美元。机构评级：截至2025年3月9日，当前有11家机构对Akero Therapeutics, Inc.目标价做出预测，其中目标均价为77.64美元，其中最低目标价为60.00美元，最高目标价为109.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"2509846704","title":"Akero Therapeutics, Inc.盘中异动 急速上涨5.05%报56.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509846704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509846704?lang=zh_cn&edition=full","pubTime":"2025-02-05 02:04","pubTimestamp":1738692290,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日02时04分，Akero Therapeutics, Inc.股票出现波动，股价急速上涨5.05%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.28%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Azitra Inc、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为1773.37%、967.33%、575.50%，振幅较大的相关个股有Azitra Inc、Cingulate Inc C/Wts 10/12/2026 、Quoin Pharmaceuticals Ltd，振幅分别为72.82%、57.14%、52.61%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205020450a2395090&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205020450a2395090&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4505","BK4585","BK4139","AKRO"],"gpt_icon":0},{"id":"2508999044","title":"瑞银：维持Akero Therapeutics(AKRO.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至109.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508999044","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508999044?lang=zh_cn&edition=full","pubTime":"2025-02-01 03:11","pubTimestamp":1738350684,"startTime":"0","endTime":"0","summary":"瑞银：维持Akero Therapeutics(AKRO.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至109.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01031147922778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"1190094789","title":"异动解读 | 主要分析师升级Akero Therapeutics评级,目标价大涨80%导致股价盘中飙升5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190094789","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190094789?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:47","pubTimestamp":1738248436,"startTime":"0","endTime":"0","summary":"生物科技公司Akero Therapeutics(AKRO)今日盘中飙升5.83%,股价一度触及56.70美元。\n\n消息面上,美银美林将该公司的股票评级上调至买入,目标价由35美元大幅上调至63美元,参与评级的12家机构中有92%给予该股买入评级,升级幅度之大引发市场强烈反应。\n\n分析师看好Akero Therapeutics潜力股,推动了公司股价今日大涨。该公司是一家临床阶段生物科技公司,正着力开发治疗非酒精性脂肪肝炎药物AKR-001,这一未满足的大疾病市场潜力巨大,预计公司长期将获得不错的增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 主要分析师升级Akero Therapeutics评级,目标价大涨80%导致股价盘中飙升5.83%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"2507629009","title":"Akero Therapeutics, Inc.盘中异动 股价大涨5.00%报56.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507629009?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:41","pubTimestamp":1738248090,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时41分，Akero Therapeutics, Inc.股票出现异动，股价急速拉升5.00%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224130a234571c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224130a234571c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AKRO","BK4505","BK4588","BK4585","LENZ"],"gpt_icon":0},{"id":"2507403206","title":"B of A Securities：上调Akero Therapeutics(AKRO.US)评级，由中性调整至买入评级, 目标价由35.00美元调整至63.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507403206","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507403206?lang=zh_cn&edition=full","pubTime":"2025-01-30 20:42","pubTimestamp":1738240955,"startTime":"0","endTime":"0","summary":"B of A Securities：上调Akero Therapeutics(AKRO.US)评级，由中性调整至买入评级, 目标价由35.00美元调整至63.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30204247909587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","AKRO"],"gpt_icon":0},{"id":"2507549176","title":"大摩：维持Akero Therapeutics(AKRO.US)评级，由增持调整至增持评级, 目标价由46.00美元调整至96.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507549176","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507549176?lang=zh_cn&edition=full","pubTime":"2025-01-29 01:31","pubTimestamp":1738085469,"startTime":"0","endTime":"0","summary":"大摩：维持Akero Therapeutics(AKRO.US)评级，由增持调整至增持评级, 目标价由46.00美元调整至96.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29013147883501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"1178007636","title":"异动解读 | 分析师看好公司前景 Akero Therapeutics盘中大涨7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178007636","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178007636?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:38","pubTimestamp":1738075112,"startTime":"0","endTime":"0","summary":"生物制药公司Akero Therapeutics今日盘中大涨7.89%,引起市场广泛关注。消息面上,近期多家分析师机构相继上调了对Akero的目标股价预期。此外,摩根大通更是将目标价从49美元大幅上调至73美元,对该公司发展前景给予高度评价。分析师为何如此看好Akero?Akero主攻非酒精性脂肪性肝病的治疗领域,该领域存在着巨大的未满足医疗需求。公司核心产品近期取得了阶段性临床试验数据,数据令人鼓舞,彰显了产品的疗效和安全性,因此市场对Akero的长期成长潜力更加看好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"112d4d8d6c9067afce5bd9a0f7d276d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"1167558922","title":"异动解读 | 分析师力挺Akero疗效 该股盘中大涨7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167558922","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167558922?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:38","pubTimestamp":1738075088,"startTime":"0","endTime":"0","summary":"生物制药股Akero Therapeutics(AKRO)今日盘中大涨7.89%,引发市场关注。\n\n多家分析师机构近期看好该公司药品前景并上调其目标股价。数据显示,卡南考德金就将AKRO的目标价从56美元大幅上调至73美元。此外,H.C.万赖特银行也将目标价从50美元上调至72美元。除此之外,摩根大通也将目标价从49美元上调至73美元,认为该公司长期前景光明。\n\n分析师的乐观评级或源自AKRO药品最新数据结果喜人,市场预期其今后能为更多肝病患者提供创新治疗。但具体分析依据目前尚不明确。不过AKRO股价大涨可见投资者备受鼓舞,对其发展信心倍增。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"2506451174","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大涨7.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506451174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506451174?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:35","pubTimestamp":1738074903,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日22时35分，Akero Therapeutics, Inc.股票出现异动，股价急速拉升7.67%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012822350498756bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012822350498756bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKRO","BK4585","LENZ","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"1130014646","title":"异动解读 | 多家分析师看好Akero前景 该股盘前大涨5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130014646","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130014646?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:10","pubTimestamp":1738073433,"startTime":"0","endTime":"0","summary":"Akero Therapeutics(AKRO)盘前股价大涨5.82%,引起市场广泛关注。公司数据显示,盘前共涨7.05美元,报127.05美元。\n这一涨势或与多家分析师机构近期上调对其目标股价预期有关。据悉,Canaccord Genuity将其目标价从56美元上调至73美元,H.C. Wainwright也从50美元上调至72美元。此外,摩根大通将目标价从49美元上调至73美元,看好该公司未来前景。\n分析师为何如此看好Akero?具体原因暂时无从得知,但市场显然对这一药企发展前景抱有信心。不过该股尚处于盘前交易阶段,后市表现如何仍有待关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"112d4d8d6c9067afce5bd9a0f7d276d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 多家分析师看好Akero前景 该股盘前大涨5.82%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akerotx.com","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":0.0094},{"period":"3month","weight":0.2163},{"period":"6month","weight":-0.0174},{"period":"1year","weight":0.7836},{"period":"ytd","weight":0.9644}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akero Therapeutics, Inc.于2017年1月根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司，专注于开发和商业化具有高度未满足医疗需求的严重代谢性疾病的变革性治疗方法。该公司最初的重点是非酒精性脂肪性肝炎，即NASH，一种没有任何批准疗法的疾病。NASH是一种严重的非酒精性脂肪肝疾病，或NAFLD，其特点是肝脏发生炎症和纤维化，可发展为肝硬化、肝衰竭、癌症和死亡。NASH是肝移植的主要原因。该公司的主要候选产品AKR-001正在开发，作为NASH患者的潜在治疗方法，是成纤维细胞生长因子21的类似物，即FGF21。FGF21是一种内源性表达的激素，调节全身脂质、碳水化合物和蛋白质的代谢。FGF21在保护许多类型的细胞免受各种形式的压力方面也发挥着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.142297},{"month":2,"riseRate":0.5,"avgChangeRate":0.000611},{"month":3,"riseRate":0,"avgChangeRate":-0.111811},{"month":4,"riseRate":0.5,"avgChangeRate":-0.025545},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.008179},{"month":6,"riseRate":0.666667,"avgChangeRate":0.065058},{"month":7,"riseRate":0.571429,"avgChangeRate":0.086398},{"month":8,"riseRate":0.714286,"avgChangeRate":0.063717},{"month":9,"riseRate":0.571429,"avgChangeRate":0.242111},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.066152},{"month":11,"riseRate":0.714286,"avgChangeRate":0.06721},{"month":12,"riseRate":0.571429,"avgChangeRate":0.066266}],"exchange":"NASDAQ","name":"Akero Therapeutics","nameEN":"Akero Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akero Therapeutics,AKRO,Akero Therapeutics股票,Akero Therapeutics股票老虎,Akero Therapeutics股票老虎国际,Akero Therapeutics行情,Akero Therapeutics股票行情,Akero Therapeutics股价,Akero Therapeutics股市,Akero Therapeutics股票价格,Akero Therapeutics股票交易,Akero Therapeutics股票购买,Akero Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}